瑞巴派特联合兰索拉唑对消化性溃疡患者炎症水平的影响  

The Effect of Rebamipide Combined with Lansoprazole on the Inflammatory Level in Patients with Peptic Ulcer

作　　者：李莹 严妍 朱惠英[1] LI Ying;YAN Yan;ZHU Huiying(Department of Pharmacy,Suzhou Municipal Hospital,Suzhou 215000,Jiangsu,China)

机构地区：[1]苏州市立医院药剂科,江苏苏州215000

出　　处：《系统医学》2025年第4期191-194,共4页Systems Medicine

摘　　要：目的研究瑞巴派特联合兰索拉唑对消化性溃疡患者炎症水平的影响。方法非随机选取苏州市立医院2022年6月—2024年5月收治的80例消化性溃疡患者为研究对象,按照用药方式不同分为两组,各40例。单药组行瑞巴派特治疗,联合组行瑞巴派特联合兰索拉唑治疗,对比两组患者治疗效果、炎症水平、不良反应、临床症状积分。结果联合组治疗总有效率为97.50%(39/40),高于单药组的80.00%(32/40),差异有统计学意义(χ^(2)=4.507,P<0.05)。联合组的炎症水平均优于单药组,不良反应发生率低于及临床症状积分均低于单药组,差异有统计学意义(P均<0.05)。结论瑞巴派特联合艾普拉唑治疗消化性溃疡患者可积极改善炎症水平与临床症状,提升治疗效果,降低不良反应发生率。Objective To study the effect of rebamipide combined with lansoprazole on the level of inflammation in patients with peptic ulcer.Methods A total of eighty patients with peptic ulcer admitted to Suzhou Municipal Hospital from June 2022 to May 2024 were non-randomly selected as research objects and divided into two groups according to different medication methods,forty cases in each group.The single drug group was treated with repakide,and the combined group was treated with repakide combined with Lansoprazole.The therapeutic effect,inflammation level,adverse reactions and clinical symptom scores were compared between the two groups.Results The total effective rate of the combined group was 97.50%(39/40),which was higher than 80.00%(32/40)of the single drug group,and the difference was statistically significant(χ^(2)=4.507,P<0.05).The inflammation level of the combined group was better than that of the single drug group,the incidence of adverse reactions was lower than that of the single drug group,and the clinical symptom score was lower than that of the single drug group,and the differences were statistically significant(all P<0.05).Conclusion Rebamipide combined with ilaprazole in the treatment of peptic ulcer patients can actively improve the level of inflammation and clinical symptoms,improve the therapeutic effect,and reduce the incidence of adverse reactions.

关 键 词：瑞巴派特 兰索拉唑 消化性溃疡 炎症水平 

分 类 号：R9[医药卫生—药学]